Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
APREA THERAPEUTICS INC APRE: 0,48
52w: 0.3310 - 4.7
https://ir.aprea.com/static-files/30f4a16e-335b-4fa5-83d1-592b0aade43f
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Aprea Therapeutics (APRE - Research Report) and set a price target of $3.00.
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is focused on developing and commercializing novel cancer therapeutics that reactivate mutant protein 53 (p53) tumor suppressor protein. The Company's lead product candidate, APR-246, or eprenetapopt, is a small molecule p53 reactivator that is in clinical development for hematologic malignancies, including myelodysplastic syndromes, or myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML). The Company's APR-548 is a second generation p53 reactivator that is a unique analog of eprenetapopt and therefore a pro-drug of MQ. APR-548 exhibits high oral bioavailability in preclinical testing and is being developed in an oral dosage form. The Company has initiated a Phase I clinical trial testing APR-548 in relapsed/refractory MDS and AML. Its solid tumor program includes its clinical trial evaluating eprenetapopt with anti-PD-1 therapy in advanced solid tumors.
Total Cash (mrq) 33.11M
Total Cash Per Share (mrq) 0.62
Total Debt (mrq) 110.55k
Shares Outstanding 53M
% Held by Insiders 24.17%
Sep 30, 2022 0.8380
Jun 30, 2022 1.2900
Apr 30, 2022 1.5500
Mar 31, 2022 2.0400
Jan 01, 2022 3.2100
Dec 01, 2021 4.7000
Sep 30, 2021 5.6700
May 31, 2021 7.8000
Dec 01, 2020 30.9910
OpGen, Inc. (OPGN) : 0.1501
52 Week Range 0.1427 - 1.4700
recent news:
https://www.globenewswire.com/news-release/2022/10/25/2540712/35690/en/OpGen-Subsidiary-Curetis-and-BioVersys-Sign-Collaboration-Agreement-for-Clinical-Trial-Support.html
Oct. 03, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or the “Company”), today announced that it has closed its previously announced registered direct offering with a single institutional investor for the purchase and sale of 9,660,000 shares of the Company’s common stock at a purchase price of $0.35 per share of common stock.
Total Cash (mrq) 10.28M
Shares Outstanding 5 53.7M
Float 48.18M
Total Cash Per Share (mrq) 0.19
Book Value Per Share (mrq) 0.29
Total assets September 30, 2022 $32,959,167 $
OpGen, Inc., a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits. The company's products also comprise ARES Technology Platform, including ARES reference database on antimicrobial resistance using next generation sequencing technology and artificial intelligence powered bioinformatics solutions for antibiotic response prediction; and Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers. The company utilizes molecular diagnostics and informatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections to enhance patient outcomes, and to decrease the spread of infections caused by multidrug-resistant microorganisms. OpGen, Inc. has a collaboration with the New York State Department of Health and ILÚM Health Solutions, LLC to develop a research program to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Rockville, Maryland.
https://www.opgen.com/
OpGen, Inc. (OPGN) : 0.1501
52 Week Range 0.1427 - 1.4700
recent news:
https://www.globenewswire.com/news-release/2022/10/25/2540712/35690/en/OpGen-Subsidiary-Curetis-and-BioVersys-Sign-Collaboration-Agreement-for-Clinical-Trial-Support.html
Oct. 03, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or the “Company”), today announced that it has closed its previously announced registered direct offering with a single institutional investor for the purchase and sale of 9,660,000 shares of the Company’s common stock at a purchase price of $0.35 per share of common stock.
Total Cash (mrq) 10.28M
Shares Outstanding 5 53.7M
Float 48.18M
Total Cash Per Share (mrq) 0.19
Book Value Per Share (mrq) 0.29
Total assets September 30, 2022 $32,959,167 $
OpGen, Inc., a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits. The company's products also comprise ARES Technology Platform, including ARES reference database on antimicrobial resistance using next generation sequencing technology and artificial intelligence powered bioinformatics solutions for antibiotic response prediction; and Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers. The company utilizes molecular diagnostics and informatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections to enhance patient outcomes, and to decrease the spread of infections caused by multidrug-resistant microorganisms. OpGen, Inc. has a collaboration with the New York State Department of Health and ILÚM Health Solutions, LLC to develop a research program to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Rockville, Maryland.
https://www.opgen.com/
APREA THERAPEUTICS INC APRE: 0,4799 +18,00%
52w: 0.3310 - 4.7
https://ir.aprea.com/static-files/30f4a16e-335b-4fa5-83d1-592b0aade43f
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is focused on developing and commercializing novel cancer therapeutics that reactivate mutant protein 53 (p53) tumor suppressor protein. The Company's lead product candidate, APR-246, or eprenetapopt, is a small molecule p53 reactivator that is in clinical development for hematologic malignancies, including myelodysplastic syndromes, or myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML). The Company's APR-548 is a second generation p53 reactivator that is a unique analog of eprenetapopt and therefore a pro-drug of MQ. APR-548 exhibits high oral bioavailability in preclinical testing and is being developed in an oral dosage form. The Company has initiated a Phase I clinical trial testing APR-548 in relapsed/refractory MDS and AML. Its solid tumor program includes its clinical trial evaluating eprenetapopt with anti-PD-1 therapy in advanced solid tumors.
Total Cash (mrq) 33.11M
Total Cash Per Share (mrq) 0.62
Total Debt (mrq) 110.55k
Shares Outstanding 53M
% Held by Insiders 1 24.17%
APREA THERAPEUTICS INC APRE: 0,4799 +18,00%
52w: 0.3310 - 4.7
https://ir.aprea.com/static-files/30f4a16e-335b-4fa5-83d1-592b0aade43f
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is focused on developing and commercializing novel cancer therapeutics that reactivate mutant protein 53 (p53) tumor suppressor protein. The Company's lead product candidate, APR-246, or eprenetapopt, is a small molecule p53 reactivator that is in clinical development for hematologic malignancies, including myelodysplastic syndromes, or myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML). The Company's APR-548 is a second generation p53 reactivator that is a unique analog of eprenetapopt and therefore a pro-drug of MQ. APR-548 exhibits high oral bioavailability in preclinical testing and is being developed in an oral dosage form. The Company has initiated a Phase I clinical trial testing APR-548 in relapsed/refractory MDS and AML. Its solid tumor program includes its clinical trial evaluating eprenetapopt with anti-PD-1 therapy in advanced solid tumors.
Total Cash (mrq) 33.11M
Total Cash Per Share (mrq) 0.62
Total Debt (mrq) 110.55k
Shares Outstanding 53M
% Held by Insiders 1 24.17%
Vascular Biogenics Ltd. (NASDAQ:VBLT)
Number of Hedge Fund Holders: 3
Share Price as of November 29: $0.15
Vascular Biogenics Ltd. (NASDAQ:VBLT) is another clinical-stage biopharmaceutical company on our list. It develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the US.
This November, Vascular Biogenics Ltd. (NASDAQ:VBLT) reported that for the third quarter, its EPS of -$0.12 was in line with estimates, while its $0.5 million revenue was up 150% year-over-year and beat estimates by $0.3 million. The company's cash, cash equivalents, short-term bank deposits, and restricted bank deposits stood at $27.7 million. This figure is expected to fund the company's current operating expenses and capital expenditures for at least 12 months.
Our hedge fund data shows three funds long Vascular Biogenics Ltd. (NASDAQ:VBLT) in the third quarter and four funds long the stock in the previous quarter. Their total stake values were $84,000 and $7.2 million, respectively.
Vascular Biogenics Ltd. (NASDAQ:VBLT)
Number of Hedge Fund Holders: 3
Share Price as of November 29: $0.15
Vascular Biogenics Ltd. (NASDAQ:VBLT) is another clinical-stage biopharmaceutical company on our list. It develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the US.
This November, Vascular Biogenics Ltd. (NASDAQ:VBLT) reported that for the third quarter, its EPS of -$0.12 was in line with estimates, while its $0.5 million revenue was up 150% year-over-year and beat estimates by $0.3 million. The company's cash, cash equivalents, short-term bank deposits, and restricted bank deposits stood at $27.7 million. This figure is expected to fund the company's current operating expenses and capital expenditures for at least 12 months.
Our hedge fund data shows three funds long Vascular Biogenics Ltd. (NASDAQ:VBLT) in the third quarter and four funds long the stock in the previous quarter. Their total stake values were $84,000 and $7.2 million, respectively.
Reshape Lifesciences (RSLS) : 0.149
52w 0.14 - 2.22
https://ir.reshapelifesciences.com/static-files/83ef3822-187c-4658-af22-cfdfeb4455f8
https://reshapecare.myshopify.com/pages/supplementproducts
Reshape Lifesciences (RSLS) : 0.149
52w 0.14 - 2.22
https://ir.reshapelifesciences.com/static-files/83ef3822-187c-4658-af22-cfdfeb4455f8
https://reshapecare.myshopify.com/pages/supplementproducts
Lordstown Motors Corp. (RIDE) :1,42 781.291 7,58%
LORDSTOWN, Ohio, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Lordstown Motors Corp. (Nasdaq: RIDE), (“Lordstown Motors” or the “Company”), an original equipment manufacturer (“OEM”) of electric light duty vehicles focused on the commercial fleet market, today announced:
Lordstown EnduranceTM full-size battery-electric pickup truck has achieved full homologation, a key condition to start sales
EPA and CARB certification has been received
FMVSS crash and non-crash testing successfully completed
First customer vehicles leaving the Foxconn EV Ohio plant for delivery
EnduranceTM advanced to finalist in the North American Truck of the Year competition
Executive Commentary
Lordstown Motors is pleased to announce that our EnduranceTM full-size battery electric pickup truck has achieved full homologation. Certification has been received from both the EPA and CARB. These were the key conditions to start customer sales. The first units, of our initial batch of 500, are leaving the Foxconn EV Ohio plant for customer delivery. As disclosed earlier, production volume will ramp slowly and accelerate as we resolve supply chain constraints.
“I am very proud of the Lordstown Motors and Foxconn EV Ohio team for their hard work, grit, and tenacity in achieving this milestone. We are very excited to start delivering vehicles to our commercial fleet customers. The EnduranceTM will provide benefits to customers that use their vehicles for work. It optimizes key attributes of traction and maneuverability - with our in-wheel hub motors, safety - with our five-star crash performance, and value in the segment,” said Edward Hightower, Lordstown CEO and President.
We are also excited to have advanced as a finalist in the North American Truck of the Year competition. We look forward to the judges’ announcement of the winner in January.
About Lordstown Motors Corp.
Lordstown Motors is an electric vehicle (EV) OEM developing innovative light duty commercial fleet vehicles, with the Endurance all electric pickup truck as its first vehicle and being launched in the Foxconn EV plant in Lordstown, Ohio. Lordstown Motors has engineering, research and development facilities in Farmington Hills, Michigan and Irvine, California. For additional information visit www.lordstownmotors.com.
Lordstown Motors Corp. (RIDE) :1,42 781.291 7,58%
LORDSTOWN, Ohio, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Lordstown Motors Corp. (Nasdaq: RIDE), (“Lordstown Motors” or the “Company”), an original equipment manufacturer (“OEM”) of electric light duty vehicles focused on the commercial fleet market, today announced:
Lordstown EnduranceTM full-size battery-electric pickup truck has achieved full homologation, a key condition to start sales
EPA and CARB certification has been received
FMVSS crash and non-crash testing successfully completed
First customer vehicles leaving the Foxconn EV Ohio plant for delivery
EnduranceTM advanced to finalist in the North American Truck of the Year competition
Executive Commentary
Lordstown Motors is pleased to announce that our EnduranceTM full-size battery electric pickup truck has achieved full homologation. Certification has been received from both the EPA and CARB. These were the key conditions to start customer sales. The first units, of our initial batch of 500, are leaving the Foxconn EV Ohio plant for customer delivery. As disclosed earlier, production volume will ramp slowly and accelerate as we resolve supply chain constraints.
“I am very proud of the Lordstown Motors and Foxconn EV Ohio team for their hard work, grit, and tenacity in achieving this milestone. We are very excited to start delivering vehicles to our commercial fleet customers. The EnduranceTM will provide benefits to customers that use their vehicles for work. It optimizes key attributes of traction and maneuverability - with our in-wheel hub motors, safety - with our five-star crash performance, and value in the segment,” said Edward Hightower, Lordstown CEO and President.
We are also excited to have advanced as a finalist in the North American Truck of the Year competition. We look forward to the judges’ announcement of the winner in January.
About Lordstown Motors Corp.
Lordstown Motors is an electric vehicle (EV) OEM developing innovative light duty commercial fleet vehicles, with the Endurance all electric pickup truck as its first vehicle and being launched in the Foxconn EV plant in Lordstown, Ohio. Lordstown Motors has engineering, research and development facilities in Farmington Hills, Michigan and Irvine, California. For additional information visit www.lordstownmotors.com.
DELTA DRONE : 0.0235
Euronext Growth Paris
FR0014009LP0 - Stock
52w: 0.0235 - 9.85
Nombre d'actions au 22/11/2022 : 13 673 910
mktcap: 340.000
Delta Drone specializes in the design, production and sale of civilian drones for professional use, intended for applications in the agriculture, mountains, industrial inspection, building and public works, mining, event, tourism and leisure sectors. The group also offers consulting, technical assistance, and maintenance services. Net sales are distributed geographically as follows: France (78.8%) and Africa (21.2%).
net sales: 18 million
DELTA DRONE : 0.0235
Euronext Growth Paris
FR0014009LP0 - Stock
52w: 0.0235 - 9.85
Nombre d'actions au 22/11/2022 : 13 673 910
mktcap: 340.000
Delta Drone specializes in the design, production and sale of civilian drones for professional use, intended for applications in the agriculture, mountains, industrial inspection, building and public works, mining, event, tourism and leisure sectors. The group also offers consulting, technical assistance, and maintenance services. Net sales are distributed geographically as follows: France (78.8%) and Africa (21.2%).
net sales: 18 million
GAOTU (GOTU) : 1.0600-0.0300 (-2.75%)
At close: November 21 04:00PM EST
Pre-Market: 1.2800 +0.22 (+20.75%)
2 year high: 149.05 (jan 2021)
Gaotu Techedu Announces Third Quarter of 2022 Unaudited Financial Results and a Share Repurchase Program
BEIJING, Nov. 22, 2022 /PRNewswire/ -- Gaotu Techedu Inc. (NYSE: GOTU) ("Gaotu" or the "Company"), a technology-driven education company and online large-class tutoring service provider in China, today announced its unaudited financial results for the third quarter ended September 30, 2022.
Third Quarter 2022 Highlights[1]
Net revenues were RMB606.2 million, compared with net revenues of RMB1,114.9 million in the same period of 2021.
Gross billings[2] were RMB607.0 million, compared with gross billings of RMB301.6 million in the same period of 2021.
Net loss was RMB61.4 million, compared with net loss of RMB1,044.6 million in the same period of 2021.
Non-GAAP net loss was RMB44.8 million, compared with non-GAAP net loss of RMB989.3 million in the same period of 2021.
Nine Months Ended September 30, 2022 Highlights
Net revenues were RMB1,868.6 million, compared with net revenues of RMB5,287.5 million in the same period of 2021.
Gross billings were RMB1,536.8 million, compared with gross billings of RMB4,177.7 million in the same period of 2021.
Net loss was RMB57.4 million, compared with net loss of RMB3,389.3 million in the same period of 2021.
Non-GAAP net income was RMB48.4 million, compared with non-GAAP net loss of RMB3,082.6 million in the same period of 2021.
Larry Xiangdong Chen, the Company's founder, Chairman and CEO, commented, "The gradual and stable increase of our net revenues is solid evidence that our new businesses are growing continuously and sustainably, which boosts our confidence in our future, and indicates that our organization is resilient and our operations are efficient. Guided by the strategy of profitable growth, we expect the growth momentum of our businesses to continue, and to see a sizable positive net operating cashflow next quarter.
Further, to demonstrate our management's unwavering confidence in our company's future development, our board of directors today authorized an up to US$30 million share repurchase program. I also intend to personally purchase up to US$20 million of our shares. Going forward, we will continue to stay true to our original aspiration to educate, continue to create value for our shareholders, continue to nurture talents for our society and continue to contribute to the educational development of China."
Shannon Shen, CFO of the Company, added, "As we continued to explore new businesses post restructuring against the backdrop of external challenges and uncertainties, we are pleased to report that our business sustained its continuous and healthy growth as we expected, driven by our deepening understanding of the vertical markets, relentless efforts to improve our operational efficiency and constant investment in teaching quality. Our net revenues in the third quarter recorded a 12.7% quarter-over-quarter increase to RMB606.2 million, and our gross billings increased 101.3% year-over-year to RMB607.0 million. Our businesses exhibit certain seasonality, with the third quarter's increase in gross billings largely contributed by new customers.
Further, our capital position remains strong. As of September 30, 2022, we had a total of approximately RMB3.3 billion in terms of cash, cash equivalents, restricted cash, and short-term investments on our balance sheet, providing ample resources for continued business development."
Financial Results for the Third Quarter of 2022
Net Revenues
Net revenues decreased by 45.6% to RMB606.2 million from RMB1,114.9 million in the third quarter of 2021. The decrease was mainly due to the organizational adjustments and business restructuring the Company performed to comply with government regulations, including the cessation of compulsory education academic subject tutoring services to students ("Business Restructuring").
Cost of Revenues
Cost of revenues decreased by 76.4% to RMB168.8 million from RMB715.2 million in the third quarter of 2021. The decline was mainly due to the reduction of employees and offices as a result of the Business Restructuring, which resulted in decreases in staff related cost, rental expenses, as well as teaching materials and bandwidth cost.
Gross Profit and Gross Margin
Gross profit was RMB437.4 million, compared with RMB399.7 million in the third quarter of 2021. Gross profit margin increased to 72.2% from 35.9% in the same period of 2021.
Non-GAAP gross profit was RMB439.3 million, compared with RMB436.9 million in the same period of 2021. Non-GAAP gross profit margin increased to 72.5% from 39.2% in the same period of 2021.
Operating Expenses
Operating expenses decreased by 65.8% to RMB506.9 million from RMB1,481.1 million in the third quarter of 2021. The decline was primarily due to the reduction of employees as a result of the Business Restructuring, as well as the losses incurred during the impairment assessment of long-lived assets and disposal of assets the Company performed in the third quarter of 2021. Moreover, the expenditure on branding and marketing activities on academic subject tutoring services also showed a large decline as a result of the changes of regulatory environment.
Selling expenses decreased to RMB336.8 million from RMB826.4 million in the third quarter of 2021.
Research and development expenses decreased to RMB106.5 million from RMB336.3 million in the third quarter of 2021.
General and administrative expenses decreased to RMB63.6 million from RMB164.7 million in the third quarter of 2021.
Impairment loss on long-lived assets decreased to nil from RMB28.6 million in the third quarter of 2021.
Disposal loss on assets decreased to nil from RMB125.0 million in the third quarter of 2021.
Loss from Operations
Loss from operations was RMB69.6 million, compared with loss from operations of RMB1,081.3 million in the third quarter of 2021, which was primarily due to a large decrease in operation related cost and expenses as a result of the Business Restructuring, as well as no impairment loss or disposal loss on assets related to Business Restructuring incurred in the third quarter.
Non-GAAP loss from operations was RMB53.0 million, compared with non-GAAP loss from operations of RMB1,026.0 million in the third quarter of 2021.
Interest Income and Realized Gains from Investments
Interest income and realized gains from investments, on aggregate, was RMB12.1 million, compared with a total of RMB35.0 million in the third quarter of 2021.
Other Income (Expenses)
Other expenses were RMB3.4 million, compared with other income of RMB1.3 million in the third quarter of 2021.
Net Loss
Net loss was RMB61.4 million, compared with net loss of RMB1,044.6 million in the third quarter of 2021.
Non-GAAP net loss was RMB44.8 million, compared with non-GAAP net loss of RMB989.3 million in the third quarter of 2021.
Cash Flow
Net operating cash outflow for the third quarter of 2022 was RMB34.7 million. The operating cash outflow in the third quarter was mainly due to staff compensation and marketing expenditure paid to enhance our market share.
Basic and Diluted Net Loss per ADS
Basic and diluted net loss per ADS were both RMB0.24 in the third quarter of 2022.
Non-GAAP basic and diluted net loss per ADS were both RMB0.17 in the third quarter of 2022.
Share Outstanding
As of September 30, 2022, the Company had 172,679,700 ordinary shares outstanding.
Cash, Cash Equivalents, Restricted Cash and Short-term Investments
As of September 30, 2022, the Company had cash and cash equivalents, restricted cash and short-term investments of RMB3,342.9 million in aggregate, compared with a total of RMB3,671.1 million as of December 31, 2021.
Other Payables
As of September 30, 2022, other payables in non-current liabilities totaled RMB26.6 million, which were payables related to the purchase of the Zhengzhou properties.
Share Repurchase Program
The Company's board of directors today authorized a share repurchase program under which the Company may repurchase up to US$30 million of its common shares, including shares represented by American depositary shares, effective until November 22, 2025. Additionally, Mr. Larry Xiangdong Chen, the Company's founder, Chairman and CEO, intends to personally purchase up to US$20 million of the Company's shares.
The Company's proposed repurchases may be made from time to time on the open market at prevailing market prices, in privately negotiated transactions, in block trades and/or through other legally permissible means, depending on market conditions and in accordance with applicable rules and regulations. The Company's board of directors will review the share repurchase program periodically, and may authorize adjustment of its terms and size. The Company plans to fund repurchases from its cash balance.
GAOTU (GOTU) : 1.0600-0.0300 (-2.75%)
At close: November 21 04:00PM EST
Pre-Market: 1.2800 +0.22 (+20.75%)
2 year high: 149.05 (jan 2021)
Gaotu Techedu Announces Third Quarter of 2022 Unaudited Financial Results and a Share Repurchase Program
BEIJING, Nov. 22, 2022 /PRNewswire/ -- Gaotu Techedu Inc. (NYSE: GOTU) ("Gaotu" or the "Company"), a technology-driven education company and online large-class tutoring service provider in China, today announced its unaudited financial results for the third quarter ended September 30, 2022.
Third Quarter 2022 Highlights[1]
Net revenues were RMB606.2 million, compared with net revenues of RMB1,114.9 million in the same period of 2021.
Gross billings[2] were RMB607.0 million, compared with gross billings of RMB301.6 million in the same period of 2021.
Net loss was RMB61.4 million, compared with net loss of RMB1,044.6 million in the same period of 2021.
Non-GAAP net loss was RMB44.8 million, compared with non-GAAP net loss of RMB989.3 million in the same period of 2021.
Nine Months Ended September 30, 2022 Highlights
Net revenues were RMB1,868.6 million, compared with net revenues of RMB5,287.5 million in the same period of 2021.
Gross billings were RMB1,536.8 million, compared with gross billings of RMB4,177.7 million in the same period of 2021.
Net loss was RMB57.4 million, compared with net loss of RMB3,389.3 million in the same period of 2021.
Non-GAAP net income was RMB48.4 million, compared with non-GAAP net loss of RMB3,082.6 million in the same period of 2021.
Larry Xiangdong Chen, the Company's founder, Chairman and CEO, commented, "The gradual and stable increase of our net revenues is solid evidence that our new businesses are growing continuously and sustainably, which boosts our confidence in our future, and indicates that our organization is resilient and our operations are efficient. Guided by the strategy of profitable growth, we expect the growth momentum of our businesses to continue, and to see a sizable positive net operating cashflow next quarter.
Further, to demonstrate our management's unwavering confidence in our company's future development, our board of directors today authorized an up to US$30 million share repurchase program. I also intend to personally purchase up to US$20 million of our shares. Going forward, we will continue to stay true to our original aspiration to educate, continue to create value for our shareholders, continue to nurture talents for our society and continue to contribute to the educational development of China."
Shannon Shen, CFO of the Company, added, "As we continued to explore new businesses post restructuring against the backdrop of external challenges and uncertainties, we are pleased to report that our business sustained its continuous and healthy growth as we expected, driven by our deepening understanding of the vertical markets, relentless efforts to improve our operational efficiency and constant investment in teaching quality. Our net revenues in the third quarter recorded a 12.7% quarter-over-quarter increase to RMB606.2 million, and our gross billings increased 101.3% year-over-year to RMB607.0 million. Our businesses exhibit certain seasonality, with the third quarter's increase in gross billings largely contributed by new customers.
Further, our capital position remains strong. As of September 30, 2022, we had a total of approximately RMB3.3 billion in terms of cash, cash equivalents, restricted cash, and short-term investments on our balance sheet, providing ample resources for continued business development."
Financial Results for the Third Quarter of 2022
Net Revenues
Net revenues decreased by 45.6% to RMB606.2 million from RMB1,114.9 million in the third quarter of 2021. The decrease was mainly due to the organizational adjustments and business restructuring the Company performed to comply with government regulations, including the cessation of compulsory education academic subject tutoring services to students ("Business Restructuring").
Cost of Revenues
Cost of revenues decreased by 76.4% to RMB168.8 million from RMB715.2 million in the third quarter of 2021. The decline was mainly due to the reduction of employees and offices as a result of the Business Restructuring, which resulted in decreases in staff related cost, rental expenses, as well as teaching materials and bandwidth cost.
Gross Profit and Gross Margin
Gross profit was RMB437.4 million, compared with RMB399.7 million in the third quarter of 2021. Gross profit margin increased to 72.2% from 35.9% in the same period of 2021.
Non-GAAP gross profit was RMB439.3 million, compared with RMB436.9 million in the same period of 2021. Non-GAAP gross profit margin increased to 72.5% from 39.2% in the same period of 2021.
Operating Expenses
Operating expenses decreased by 65.8% to RMB506.9 million from RMB1,481.1 million in the third quarter of 2021. The decline was primarily due to the reduction of employees as a result of the Business Restructuring, as well as the losses incurred during the impairment assessment of long-lived assets and disposal of assets the Company performed in the third quarter of 2021. Moreover, the expenditure on branding and marketing activities on academic subject tutoring services also showed a large decline as a result of the changes of regulatory environment.
Selling expenses decreased to RMB336.8 million from RMB826.4 million in the third quarter of 2021.
Research and development expenses decreased to RMB106.5 million from RMB336.3 million in the third quarter of 2021.
General and administrative expenses decreased to RMB63.6 million from RMB164.7 million in the third quarter of 2021.
Impairment loss on long-lived assets decreased to nil from RMB28.6 million in the third quarter of 2021.
Disposal loss on assets decreased to nil from RMB125.0 million in the third quarter of 2021.
Loss from Operations
Loss from operations was RMB69.6 million, compared with loss from operations of RMB1,081.3 million in the third quarter of 2021, which was primarily due to a large decrease in operation related cost and expenses as a result of the Business Restructuring, as well as no impairment loss or disposal loss on assets related to Business Restructuring incurred in the third quarter.
Non-GAAP loss from operations was RMB53.0 million, compared with non-GAAP loss from operations of RMB1,026.0 million in the third quarter of 2021.
Interest Income and Realized Gains from Investments
Interest income and realized gains from investments, on aggregate, was RMB12.1 million, compared with a total of RMB35.0 million in the third quarter of 2021.
Other Income (Expenses)
Other expenses were RMB3.4 million, compared with other income of RMB1.3 million in the third quarter of 2021.
Net Loss
Net loss was RMB61.4 million, compared with net loss of RMB1,044.6 million in the third quarter of 2021.
Non-GAAP net loss was RMB44.8 million, compared with non-GAAP net loss of RMB989.3 million in the third quarter of 2021.
Cash Flow
Net operating cash outflow for the third quarter of 2022 was RMB34.7 million. The operating cash outflow in the third quarter was mainly due to staff compensation and marketing expenditure paid to enhance our market share.
Basic and Diluted Net Loss per ADS
Basic and diluted net loss per ADS were both RMB0.24 in the third quarter of 2022.
Non-GAAP basic and diluted net loss per ADS were both RMB0.17 in the third quarter of 2022.
Share Outstanding
As of September 30, 2022, the Company had 172,679,700 ordinary shares outstanding.
Cash, Cash Equivalents, Restricted Cash and Short-term Investments
As of September 30, 2022, the Company had cash and cash equivalents, restricted cash and short-term investments of RMB3,342.9 million in aggregate, compared with a total of RMB3,671.1 million as of December 31, 2021.
Other Payables
As of September 30, 2022, other payables in non-current liabilities totaled RMB26.6 million, which were payables related to the purchase of the Zhengzhou properties.
Share Repurchase Program
The Company's board of directors today authorized a share repurchase program under which the Company may repurchase up to US$30 million of its common shares, including shares represented by American depositary shares, effective until November 22, 2025. Additionally, Mr. Larry Xiangdong Chen, the Company's founder, Chairman and CEO, intends to personally purchase up to US$20 million of the Company's shares.
The Company's proposed repurchases may be made from time to time on the open market at prevailing market prices, in privately negotiated transactions, in block trades and/or through other legally permissible means, depending on market conditions and in accordance with applicable rules and regulations. The Company's board of directors will review the share repurchase program periodically, and may authorize adjustment of its terms and size. The Company plans to fund repurchases from its cash balance.
Prom Resources
https://www.otcmarkets.com/otcapi/company/financial-report/351350/content
PRMO : 0.0003
NO DEBT!!
NEW WEBSITE: https://www.promrestaurants.com
Prom Resources, Inc.
https://www.barchart.com/stocks/quotes/PRMO/technical-chart?plot=CANDLE&volume=total&data=DO&density=M&pricesOn=1&asPctChange=0&logscale=0&indicators=ACCUM;HLMA(10,8);SMA(20);BBANDS(20,2);RSI(14,100);STOSL(14,3);SMACD(12,26,9);MOMENT(20);MFI(14,100);SMA(20)&sym=PRMO&grid=1&height=500&studyheight=100
Twitter:
$PRMO 🧐 Low trip staying on top of filings and regulatory items. Balance sheet looks good and $3Mil market cap sitting here. I’m liking the future and risk reward here. Why go through the processes if there wasn’t something coming? 😎https://t.co/qLWQcNf2Mh
— Nickeli (@nickeli54) November 14, 2022
Prom Resources
https://www.otcmarkets.com/otcapi/company/financial-report/351350/content
PRMO : 0.0003
NO DEBT!!
NEW WEBSITE: https://www.promrestaurants.com
Prom Resources, Inc.
https://www.barchart.com/stocks/quotes/PRMO/technical-chart?plot=CANDLE&volume=total&data=DO&density=M&pricesOn=1&asPctChange=0&logscale=0&indicators=ACCUM;HLMA(10,8);SMA(20);BBANDS(20,2);RSI(14,100);STOSL(14,3);SMACD(12,26,9);MOMENT(20);MFI(14,100);SMA(20)&sym=PRMO&grid=1&height=500&studyheight=100
Twitter:
$PRMO 🧐 Low trip staying on top of filings and regulatory items. Balance sheet looks good and $3Mil market cap sitting here. I’m liking the future and risk reward here. Why go through the processes if there wasn’t something coming? 😎https://t.co/qLWQcNf2Mh
— Nickeli (@nickeli54) November 14, 2022
NEOVACS (ALNEV) : 0.014
52w: 0.0135 - 14.0000
Chemical/Pharmaceutical/Health
ISIN: FR00140077X1
Neovacs SA is a France-based company active in the biotechnology industry. It specializes in immunotherapy domain and providing treatment for autoimmune and inflammatory diseases. The Company researches and develops Kinoids, drug-candidates which aim to treat disease by including an antibody response in the patient. The Company focuses its development effort on two Kinoids for Crohn’s disease, Rheumatoid Arthritis and lupus disease. Neovacs SA’s portfolio of products includes TNF-Kinoids, IFN-Kinoids and VEGF-Kinoids. The Company operates in France and the United States. In May 2016, the Company signed a joint venture agreement with Stellar Biotechnologies Inc to create Neostell, owned by the Company in 70%.
https://www.neovacs.com/fr/ (no Englisch update)
NEOVACS (ALNEV) : 0.014
52w: 0.0135 - 14.0000
Chemical/Pharmaceutical/Health
ISIN: FR00140077X1
Neovacs SA is a France-based company active in the biotechnology industry. It specializes in immunotherapy domain and providing treatment for autoimmune and inflammatory diseases. The Company researches and develops Kinoids, drug-candidates which aim to treat disease by including an antibody response in the patient. The Company focuses its development effort on two Kinoids for Crohn’s disease, Rheumatoid Arthritis and lupus disease. Neovacs SA’s portfolio of products includes TNF-Kinoids, IFN-Kinoids and VEGF-Kinoids. The Company operates in France and the United States. In May 2016, the Company signed a joint venture agreement with Stellar Biotechnologies Inc to create Neostell, owned by the Company in 70%.
https://www.neovacs.com/fr/ (no Englisch update)
Vascular Biogenics Ltd. (VBLT):
0.1358+0.0158 (+13.17%)
Continued progress on previously announced strategic process to maximize shareholder value
TEL AVIV, Israel and NEW YORK, Nov. 14, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical stage biotechnology company developing targeted medicines for immune-inflammatory diseases, today announced financial results for the third quarter ended September 30, 2022, and provided a corporate update.
“VBL’s management team and board continue to make good progress on the evaluation of strategic options for the company’s assets, including the GMP manufacturing facility and VB-601 program, with the goal of maximizing shareholder value,” said Dror Harats, M.D., Chief Executive Officer of VBL. “We recently submitted our regulatory filings for a first-in-human clinical trial for the VB-601 program, and expect to initiate this trial in the first quarter of 2023, subject to the outcome of our strategic process.”
Third Quarter Highlights
Filed a regulatory submission to the Israel Ministry of Health and institutional review board to conduct a Phase 1 first-in-human trial for its lead immunology product candidate,VB-601, a targeted antibody for immune-inflammatory applications.
Retained Chardan Capital to act as financial advisor to explore and evaluate strategic options for maximizing shareholder value.
Took steps to preserve capital, including the workforce reduction and ceasing internal development of ofra-vec.
Financial Results for the Third Quarter of 2022
At September 30, 2022, VBL had cash, cash equivalents, short-term bank deposits and restricted bank deposits of $27.7 million. VBL expects that its cash, cash equivalents, short-term bank deposits, and restricted bank deposits will be sufficient to fund currently planned operating expenses and capital expenditures for at least twelve months. VBL’s ongoing review of its strategic options and any transactions resulting from such review may impact this projection.
For the quarter ended September 30, 2022, VBL reported a net loss of $9.2 million, or ($0.12) per basic share, compared to a net loss of $6.1 million, or ($0.09) per basic share, in the comparable period in 2021.
Revenues for the quarter ended September 30, 2022, were $0.5 million, as compared to $0.2 million in the comparable period in 2021.
For the quarter ended September 30, 2022, total operating expenses were approximately $9.7 million, consisting of $6.0 million in research and development expenses, net, and $3.7 million in general and administrative expenses. This compares with total operating expenses of $6.6 million in the quarter ended September 30, 2021, which was comprised of $5.0 million in research and development expenses, net, and $1.6 million in general and administrative expenses.
About VBL Therapeutics
VBL Therapeutics (Nasdaq: VBLT) is developing targeted therapies for immune-inflammatory diseases. VBL’s lead immunology product candidate VB-601 is a targeted antibody for immune-inflammatory applications that has shown disease-modifying activity across multiple preclinical models including multiple sclerosis, rheumatoid arthritis and inflammatory bowel disease. At present, VBL is evaluating options for development of its assets, which may include partnering and other strategic options. To learn more about VBL, please visit vblrx.com or follow VBL on LinkedIn, Twitter, YouTube or Facebook.
Vascular Biogenics Ltd. (VBLT):
0.1358+0.0158 (+13.17%)
Continued progress on previously announced strategic process to maximize shareholder value
TEL AVIV, Israel and NEW YORK, Nov. 14, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical stage biotechnology company developing targeted medicines for immune-inflammatory diseases, today announced financial results for the third quarter ended September 30, 2022, and provided a corporate update.
“VBL’s management team and board continue to make good progress on the evaluation of strategic options for the company’s assets, including the GMP manufacturing facility and VB-601 program, with the goal of maximizing shareholder value,” said Dror Harats, M.D., Chief Executive Officer of VBL. “We recently submitted our regulatory filings for a first-in-human clinical trial for the VB-601 program, and expect to initiate this trial in the first quarter of 2023, subject to the outcome of our strategic process.”
Third Quarter Highlights
Filed a regulatory submission to the Israel Ministry of Health and institutional review board to conduct a Phase 1 first-in-human trial for its lead immunology product candidate,VB-601, a targeted antibody for immune-inflammatory applications.
Retained Chardan Capital to act as financial advisor to explore and evaluate strategic options for maximizing shareholder value.
Took steps to preserve capital, including the workforce reduction and ceasing internal development of ofra-vec.
Financial Results for the Third Quarter of 2022
At September 30, 2022, VBL had cash, cash equivalents, short-term bank deposits and restricted bank deposits of $27.7 million. VBL expects that its cash, cash equivalents, short-term bank deposits, and restricted bank deposits will be sufficient to fund currently planned operating expenses and capital expenditures for at least twelve months. VBL’s ongoing review of its strategic options and any transactions resulting from such review may impact this projection.
For the quarter ended September 30, 2022, VBL reported a net loss of $9.2 million, or ($0.12) per basic share, compared to a net loss of $6.1 million, or ($0.09) per basic share, in the comparable period in 2021.
Revenues for the quarter ended September 30, 2022, were $0.5 million, as compared to $0.2 million in the comparable period in 2021.
For the quarter ended September 30, 2022, total operating expenses were approximately $9.7 million, consisting of $6.0 million in research and development expenses, net, and $3.7 million in general and administrative expenses. This compares with total operating expenses of $6.6 million in the quarter ended September 30, 2021, which was comprised of $5.0 million in research and development expenses, net, and $1.6 million in general and administrative expenses.
About VBL Therapeutics
VBL Therapeutics (Nasdaq: VBLT) is developing targeted therapies for immune-inflammatory diseases. VBL’s lead immunology product candidate VB-601 is a targeted antibody for immune-inflammatory applications that has shown disease-modifying activity across multiple preclinical models including multiple sclerosis, rheumatoid arthritis and inflammatory bowel disease. At present, VBL is evaluating options for development of its assets, which may include partnering and other strategic options. To learn more about VBL, please visit vblrx.com or follow VBL on LinkedIn, Twitter, YouTube or Facebook.
TME Tencent Music Entertainment Group
5.17 +0.72 +16.18%
Tencent Music Entertainment Group (NYSE: TME) reported third-quarter revenue growth of 5.6% year-on-year to $1.04 billion, missing the consensus of $1.23 billion.
Revenues from online music services increased by 18.8% Y/Y to $482 million, driven by solid growth in music subscription revenues. ARPPU remained stable.
Revenues from social entertainment services and others decreased by 20.0% Y/Y to $553 million. ARPPU increased by 8.2% Y/Y while paying users of social entertainment services decreased by 26.0% Y/Y.
Gross margin expanded by 300 bps to 32.6%.
Non-GAAP EPS of $0.12 beat the consensus of $0.07.
Tencent held $3.58 billion in cash and equivalents.
Cussion Pang, Executive Chairman, said, "Furthermore, completing our listing on the Main Board of The Stock Exchange of Hong Kong, in addition to our primary listing on the NYSE, demonstrates our commitment to protecting long-term value for shareholders."
TME Tencent Music Entertainment Group
5.17 +0.72 +16.18%
Tencent Music Entertainment Group (NYSE: TME) reported third-quarter revenue growth of 5.6% year-on-year to $1.04 billion, missing the consensus of $1.23 billion.
Revenues from online music services increased by 18.8% Y/Y to $482 million, driven by solid growth in music subscription revenues. ARPPU remained stable.
Revenues from social entertainment services and others decreased by 20.0% Y/Y to $553 million. ARPPU increased by 8.2% Y/Y while paying users of social entertainment services decreased by 26.0% Y/Y.
Gross margin expanded by 300 bps to 32.6%.
Non-GAAP EPS of $0.12 beat the consensus of $0.07.
Tencent held $3.58 billion in cash and equivalents.
Cussion Pang, Executive Chairman, said, "Furthermore, completing our listing on the Main Board of The Stock Exchange of Hong Kong, in addition to our primary listing on the NYSE, demonstrates our commitment to protecting long-term value for shareholders."
GOTU:
huge volume, more than 500.000 after 1 minute:
GAOTU TECHEDU INC -A- ADR $1.01 15-11-2022 736.492 13,64%
2 year high: $142
Gaotu Techedu Inc, formerly GSX Techedu Inc, is a China-based holding company principally involved in the provision of technology-driven education services. Through its subsidiaries, the Company is engaged in the provision of online K-12 after-school tutoring services. It also offers foreign language, professional and interest courses. The Company conducts its businesses in Mainland China.
GOTU:
huge volume, more than 500.000 after 1 minute:
GAOTU TECHEDU INC -A- ADR $1.01 15-11-2022 736.492 13,64%
2 year high: $142
Gaotu Techedu Inc, formerly GSX Techedu Inc, is a China-based holding company principally involved in the provision of technology-driven education services. Through its subsidiaries, the Company is engaged in the provision of online K-12 after-school tutoring services. It also offers foreign language, professional and interest courses. The Company conducts its businesses in Mainland China.
ONVO: 1.58
premarket: 1.71
52w 1.50 - 5.60
5year high: 41.80
SAN DIEGO, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), a three-dimensional biology (3D biology) company focused on delivering scientific and medical breakthroughs using novel technologies including 3D bioprinting, today announced that it has successfully advanced the use of its first inflammatory bowel disease (IBD) model and has achieved the next milestone, target validation. The company announced in May 2022 that it had achieved a successful Crohn’s disease model that demonstrates key aspects of patient biology that differ from a non-diseased state and that the model would be used to find and characterize therapeutics. The Crohn’s disease model has since been utilized to understand the biology of disease and identify specific gene targets. Treating some of those targets, by introducing a compound directly to the 3D tissue model that affects the target, has now been shown to reproducibly reduce disease. Multiple targets are now considered validated, and they represent specific druggable opportunities that the company plans to leverage. Organovo plans to advance at least one target program to medicinal chemistry by the end of 2022 to build a proprietary new drug for Crohn’s disease.
“The Organovo team has successfully identified disease regulated genes from our Crohn's disease model and importantly, identified a subset that are disease-driver genes,” said Jeff Miner, Ph.D., Organovo’s Chief Scientific Officer. “These disease-drivers directly affect the disease when modulated and represent superb therapeutic targets” he added.
Organovo Executive Chairman Keith Murphy commented, “Organovo’s progress towards our goal has been driven by a strong, dedicated scientific team that has continued to rapidly advance our programs. We are pleased to have this step completed earlier than expected, and plan to continue to meet or exceed stockholder expectations as we move therapeutics to the clinic to meet unmet medical needs.”
In September 2020, Organovo announced that it had updated its business model to capitalize on its human 3D tissue technologies in drug discovery, building disease models to find effective therapies that are more likely to succeed in the clinic than drugs discovered using animal models. We have focused on the creation of three-dimensional intestinal disease models to discover therapeutic opportunities that leverage the insights possible from the truer human biology achievable in 3D human disease models.
More than 1 million people in North America suffer from Crohn’s and its prevalence is increasing globally. Because of its progressive nature, more than 70% will require at least one surgical intervention to relieve symptoms. Current drugs can slow progression in about 50% of patients, but none are curative. Defects in the intestinal lining and inflammation can lead to abdominal pain, severe diarrhea, fatigue, weight loss, malnutrition, and lower quality of life. Chronic inflammation leads to ulcers, fistulas and bowel obstructions caused by fibrosis. Organovo believes that its 3D tissue technologies are well suited to drug and target discovery in IBD because they contain a functional intestinal epithelium that is affected by disease and a stromal layer demonstrating disease-dependent fibrosis, key targets for therapy.
The drug discovery process using 3D tissues consists of several stages. Two early steps that are uniquely important in Organovo’s approach to drug discovery are creation of a disease model followed by target discovery and validation. The steps involved in each require groundbreaking science that involves the application of tools specific to our approach. We believe the achievement of these goals represents a strong step forward and lowering of risk. The remaining steps after validation of a target are typical pharma development steps to advance a drug to Phase 1 clinical trials. The next phase will be medicinal chemistry, the creation and evaluation of new chemical entities to pick the best drug candidate. Organovo plans to do this work through an outside contract research organization. Organovo is on track to have its medicinal chemistry program result in an investigative new drug (IND) application by 2025 in alignment with our previously communicated objective to have multiple INDs by that time.
Medicinal chemistry, preclinical safety studies, and other common tasks that follow consist of common practices across pharmaceutical development, and are not unique to 3D drug discovery, but can benefit greatly from the additional insights that can be provided by testing candidates in human tissue 3D models as the candidates are screened and developed. Since these steps are more typical, the risk profile is similar to traditional pharmaceutical development at these stages. However, upon entering the clinic and seeking evidence of efficacy in humans, we believe that our use of human 3D disease models to select drug candidates will result in significantly higher probability of success.
Organovo is working on additional IBD disease models representing different aspects of disease, each of which can represent a significant advancement over previous tools. We will also seek to leverage validated targets and scientific knowledge from these disease models into business development deals and partnerships with pharmaceutical companies.
About Organovo
Organovo is an early-stage biotechnology company that is developing and utilizing highly customized 3D human tissues as dynamic models of healthy and diseased human biology for drug development. The company’s proprietary technology is being used to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function and disease. Organovo’s advances include cell type-specific compartments, prevalent intercellular tight junctions, and the formation of microvascular structures. Management believes these attributes can enable critical complex, multicellular disease models that can be used to develop clinically effective drugs for selected therapeutic areas.
ONVO: 1.58
premarket: 1.71
52w 1.50 - 5.60
5year high: 41.80
SAN DIEGO, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), a three-dimensional biology (3D biology) company focused on delivering scientific and medical breakthroughs using novel technologies including 3D bioprinting, today announced that it has successfully advanced the use of its first inflammatory bowel disease (IBD) model and has achieved the next milestone, target validation. The company announced in May 2022 that it had achieved a successful Crohn’s disease model that demonstrates key aspects of patient biology that differ from a non-diseased state and that the model would be used to find and characterize therapeutics. The Crohn’s disease model has since been utilized to understand the biology of disease and identify specific gene targets. Treating some of those targets, by introducing a compound directly to the 3D tissue model that affects the target, has now been shown to reproducibly reduce disease. Multiple targets are now considered validated, and they represent specific druggable opportunities that the company plans to leverage. Organovo plans to advance at least one target program to medicinal chemistry by the end of 2022 to build a proprietary new drug for Crohn’s disease.
“The Organovo team has successfully identified disease regulated genes from our Crohn's disease model and importantly, identified a subset that are disease-driver genes,” said Jeff Miner, Ph.D., Organovo’s Chief Scientific Officer. “These disease-drivers directly affect the disease when modulated and represent superb therapeutic targets” he added.
Organovo Executive Chairman Keith Murphy commented, “Organovo’s progress towards our goal has been driven by a strong, dedicated scientific team that has continued to rapidly advance our programs. We are pleased to have this step completed earlier than expected, and plan to continue to meet or exceed stockholder expectations as we move therapeutics to the clinic to meet unmet medical needs.”
In September 2020, Organovo announced that it had updated its business model to capitalize on its human 3D tissue technologies in drug discovery, building disease models to find effective therapies that are more likely to succeed in the clinic than drugs discovered using animal models. We have focused on the creation of three-dimensional intestinal disease models to discover therapeutic opportunities that leverage the insights possible from the truer human biology achievable in 3D human disease models.
More than 1 million people in North America suffer from Crohn’s and its prevalence is increasing globally. Because of its progressive nature, more than 70% will require at least one surgical intervention to relieve symptoms. Current drugs can slow progression in about 50% of patients, but none are curative. Defects in the intestinal lining and inflammation can lead to abdominal pain, severe diarrhea, fatigue, weight loss, malnutrition, and lower quality of life. Chronic inflammation leads to ulcers, fistulas and bowel obstructions caused by fibrosis. Organovo believes that its 3D tissue technologies are well suited to drug and target discovery in IBD because they contain a functional intestinal epithelium that is affected by disease and a stromal layer demonstrating disease-dependent fibrosis, key targets for therapy.
The drug discovery process using 3D tissues consists of several stages. Two early steps that are uniquely important in Organovo’s approach to drug discovery are creation of a disease model followed by target discovery and validation. The steps involved in each require groundbreaking science that involves the application of tools specific to our approach. We believe the achievement of these goals represents a strong step forward and lowering of risk. The remaining steps after validation of a target are typical pharma development steps to advance a drug to Phase 1 clinical trials. The next phase will be medicinal chemistry, the creation and evaluation of new chemical entities to pick the best drug candidate. Organovo plans to do this work through an outside contract research organization. Organovo is on track to have its medicinal chemistry program result in an investigative new drug (IND) application by 2025 in alignment with our previously communicated objective to have multiple INDs by that time.
Medicinal chemistry, preclinical safety studies, and other common tasks that follow consist of common practices across pharmaceutical development, and are not unique to 3D drug discovery, but can benefit greatly from the additional insights that can be provided by testing candidates in human tissue 3D models as the candidates are screened and developed. Since these steps are more typical, the risk profile is similar to traditional pharmaceutical development at these stages. However, upon entering the clinic and seeking evidence of efficacy in humans, we believe that our use of human 3D disease models to select drug candidates will result in significantly higher probability of success.
Organovo is working on additional IBD disease models representing different aspects of disease, each of which can represent a significant advancement over previous tools. We will also seek to leverage validated targets and scientific knowledge from these disease models into business development deals and partnerships with pharmaceutical companies.
About Organovo
Organovo is an early-stage biotechnology company that is developing and utilizing highly customized 3D human tissues as dynamic models of healthy and diseased human biology for drug development. The company’s proprietary technology is being used to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function and disease. Organovo’s advances include cell type-specific compartments, prevalent intercellular tight junctions, and the formation of microvascular structures. Management believes these attributes can enable critical complex, multicellular disease models that can be used to develop clinically effective drugs for selected therapeutic areas.
Prom Resources
PRMO : 0.0003
NO DEBT!!
https://www.otcmarkets.com/otcapi/company/financial-report/342698/content
PRMO is Pink Current again!
https://www.otcmarkets.com/stock/PRMO/overview
NEW WEBSITE: https://www.promrestaurants.com
Prom Resources, Inc.
https://www.barchart.com/stocks/quotes/PRMO/technical-chart?plot=CANDLE&volume=total&data=DO&density=M&pricesOn=1&asPctChange=0&logscale=0&indicators=ACCUM;HLMA(10,8);SMA(20);BBANDS(20,2);RSI(14,100);STOSL(14,3);SMACD(12,26,9);MOMENT(20);MFI(14,100);SMA(20)&sym=PRMO&grid=1&height=500&studyheight=100
Twitter:
https://twitter.com/johnvsuter/status/1585070526019817473$PRMO looks like the sellings stopped. One PR or volume spike takes it a few ticks imo
— FisherTrades (@Fisher_Trades) October 27, 2022
Good morning. Nice to see $PRMO is catching eyes again.
— Broker Amanda (@DFWagent) October 24, 2022
$PRMO many are sleeping on
— Bill's Stocks and Thoughts (@billsstocks1) September 23, 2022
— Bill's Stocks and Thoughts (@billsstocks1) September 20, 2022
Vamos $PRMO https://t.co/5FiYwrYKfi
— FOX (@Jorgeemartineze) September 20, 2022
$SNMN strong support @ 0.0006$NWPN strong support @ 0.0005 with multiple news catalyst $PRMO 0.0003 holding nicely
— Savage (@KEdelbrock) September 13, 2022
$PRMO Everyone is Buying the Dip Right Now.Hoarding Shares,... https://t.co/mNJLOKlEGH
— Anita Mccormick (@AnitaMc26910087) September 13, 2022
Starting to load $PAOG. $PRMO has great chart potential on an 0004 break. Plus PRMO has the custodian that ran SPOM big back in the day
— Bill's Stocks and Thoughts (@billsstocks1) September 9, 2022
$prmo
— mike ferr (@ferrante821) September 10, 2022
The loading is off the hook
Sooner or later it will run
$VNUE After Christmas went from 0037 to 012 on almost nothing. A couple weeks later, it went to over 04 under worse fundamentals.$PRMO still haven't been filled by the whackers but I'm happy with 14MM
— Bill's Stocks and Thoughts (@billsstocks1) September 6, 2022
$PRMO
— DB Daytrades (@DB_Daytrades) September 6, 2022
Daily view of levels of interest. Need buyers to step in and break T5, I expect the day this happens we see immense volume step in and form T4 as a new based support moving forward. Alerts on watch. pic.twitter.com/FrOcPqeXzx
Ok let’s get $PRMO going soon 😎
— 🇵🇭PinayTigerTrades🗯 (@Brown_chickHB) September 1, 2022
$BYOC far from done. $PRMO chart indicating it could be next
— Bill's Stocks and Thoughts (@billsstocks1) August 31, 2022
Event based run with $CZNI vibes, possibly more. Volume precedes price on the chart. Also watching $PRMO (same custodian as the guy who ran $SPOM big back in 2020) for a trips run. Let's go $BYOC.
— Bill's Stocks and Thoughts (@billsstocks1) August 31, 2022
Prom Resources
PRMO : 0.0003
NO DEBT!!
https://www.otcmarkets.com/otcapi/company/financial-report/342698/content
PRMO is Pink Current again!
https://www.otcmarkets.com/stock/PRMO/overview
NEW WEBSITE: https://www.promrestaurants.com
Prom Resources, Inc.
https://www.barchart.com/stocks/quotes/PRMO/technical-chart?plot=CANDLE&volume=total&data=DO&density=M&pricesOn=1&asPctChange=0&logscale=0&indicators=ACCUM;HLMA(10,8);SMA(20);BBANDS(20,2);RSI(14,100);STOSL(14,3);SMACD(12,26,9);MOMENT(20);MFI(14,100);SMA(20)&sym=PRMO&grid=1&height=500&studyheight=100
Twitter:
https://twitter.com/johnvsuter/status/1585070526019817473$PRMO looks like the sellings stopped. One PR or volume spike takes it a few ticks imo
— FisherTrades (@Fisher_Trades) October 27, 2022
Good morning. Nice to see $PRMO is catching eyes again.
— Broker Amanda (@DFWagent) October 24, 2022
$PRMO many are sleeping on
— Bill's Stocks and Thoughts (@billsstocks1) September 23, 2022
— Bill's Stocks and Thoughts (@billsstocks1) September 20, 2022
Vamos $PRMO https://t.co/5FiYwrYKfi
— FOX (@Jorgeemartineze) September 20, 2022
$SNMN strong support @ 0.0006$NWPN strong support @ 0.0005 with multiple news catalyst $PRMO 0.0003 holding nicely
— Savage (@KEdelbrock) September 13, 2022
$PRMO Everyone is Buying the Dip Right Now.Hoarding Shares,... https://t.co/mNJLOKlEGH
— Anita Mccormick (@AnitaMc26910087) September 13, 2022
Starting to load $PAOG. $PRMO has great chart potential on an 0004 break. Plus PRMO has the custodian that ran SPOM big back in the day
— Bill's Stocks and Thoughts (@billsstocks1) September 9, 2022
$prmo
— mike ferr (@ferrante821) September 10, 2022
The loading is off the hook
Sooner or later it will run
$VNUE After Christmas went from 0037 to 012 on almost nothing. A couple weeks later, it went to over 04 under worse fundamentals.$PRMO still haven't been filled by the whackers but I'm happy with 14MM
— Bill's Stocks and Thoughts (@billsstocks1) September 6, 2022
$PRMO
— DB Daytrades (@DB_Daytrades) September 6, 2022
Daily view of levels of interest. Need buyers to step in and break T5, I expect the day this happens we see immense volume step in and form T4 as a new based support moving forward. Alerts on watch. pic.twitter.com/FrOcPqeXzx
Ok let’s get $PRMO going soon 😎
— 🇵🇭PinayTigerTrades🗯 (@Brown_chickHB) September 1, 2022
$BYOC far from done. $PRMO chart indicating it could be next
— Bill's Stocks and Thoughts (@billsstocks1) August 31, 2022
Event based run with $CZNI vibes, possibly more. Volume precedes price on the chart. Also watching $PRMO (same custodian as the guy who ran $SPOM big back in 2020) for a trips run. Let's go $BYOC.
— Bill's Stocks and Thoughts (@billsstocks1) August 31, 2022
AMC ENTERTAINMENT
APE: 1.35 - 3.21
4 months high 10.5
AMC Entertainment Holdings, Inc. is a theatrical exhibition company. The Company is principally engaged in the theatrical exhibition business and owns, operates, or has interests in theaters primarily located in the United States and Europe. The Company operates through two segments: U.S. markets and International markets. In U.S. markets segment, it owns, leases and operates theaters in approximately 43 states and the District of Columbia. The International markets segment has operations in or partial interest in theaters in the United Kingdom, Germany, Spain, Italy, Ireland, Portugal, Sweden, Finland, Norway, Denmark, and Saudi Arabia. Its brands include AMC, AMC CLASSIC and AMC DINE-IN. It also offers food and beverage products that include meals, healthy snacks, liquor, beer and wine options, and other gourmet products. It operates approximately 946 theaters across 10,562 screens in United States and international markets.
AMC ENTERTAINMENT
APE: 1.35 - 3.21
4 months high 10.5
AMC Entertainment Holdings, Inc. is a theatrical exhibition company. The Company is principally engaged in the theatrical exhibition business and owns, operates, or has interests in theaters primarily located in the United States and Europe. The Company operates through two segments: U.S. markets and International markets. In U.S. markets segment, it owns, leases and operates theaters in approximately 43 states and the District of Columbia. The International markets segment has operations in or partial interest in theaters in the United Kingdom, Germany, Spain, Italy, Ireland, Portugal, Sweden, Finland, Norway, Denmark, and Saudi Arabia. Its brands include AMC, AMC CLASSIC and AMC DINE-IN. It also offers food and beverage products that include meals, healthy snacks, liquor, beer and wine options, and other gourmet products. It operates approximately 946 theaters across 10,562 screens in United States and international markets.
Prom Resources
PRMO : 0.0003
NO DEBT!!
https://www.otcmarkets.com/otcapi/company/financial-report/342698/content
PRMO is Pink Current again!
https://www.otcmarkets.com/stock/PRMO/overview
NEW WEBSITE: https://www.promrestaurants.com
Prom Resources, Inc.
https://www.barchart.com/stocks/quotes/PRMO/technical-chart?plot=CANDLE&volume=total&data=DO&density=M&pricesOn=1&asPctChange=0&logscale=0&indicators=ACCUM;HLMA(10,8);SMA(20);BBANDS(20,2);RSI(14,100);STOSL(14,3);SMACD(12,26,9);MOMENT(20);MFI(14,100);SMA(20)&sym=PRMO&grid=1&height=500&studyheight=100
Twitter:
https://twitter.com/johnvsuter/status/1585070526019817473$PRMO looks like the sellings stopped. One PR or volume spike takes it a few ticks imo
— FisherTrades (@Fisher_Trades) October 27, 2022
Good morning. Nice to see $PRMO is catching eyes again.
— Broker Amanda (@DFWagent) October 24, 2022
$PRMO many are sleeping on
— Bill's Stocks and Thoughts (@billsstocks1) September 23, 2022
— Bill's Stocks and Thoughts (@billsstocks1) September 20, 2022
Vamos $PRMO https://t.co/5FiYwrYKfi
— FOX (@Jorgeemartineze) September 20, 2022
$SNMN strong support @ 0.0006$NWPN strong support @ 0.0005 with multiple news catalyst $PRMO 0.0003 holding nicely
— Savage (@KEdelbrock) September 13, 2022
$PRMO Everyone is Buying the Dip Right Now.Hoarding Shares,... https://t.co/mNJLOKlEGH
— Anita Mccormick (@AnitaMc26910087) September 13, 2022
Starting to load $PAOG. $PRMO has great chart potential on an 0004 break. Plus PRMO has the custodian that ran SPOM big back in the day
— Bill's Stocks and Thoughts (@billsstocks1) September 9, 2022
$prmo
— mike ferr (@ferrante821) September 10, 2022
The loading is off the hook
Sooner or later it will run
$VNUE After Christmas went from 0037 to 012 on almost nothing. A couple weeks later, it went to over 04 under worse fundamentals.$PRMO still haven't been filled by the whackers but I'm happy with 14MM
— Bill's Stocks and Thoughts (@billsstocks1) September 6, 2022
$PRMO
— DB Daytrades (@DB_Daytrades) September 6, 2022
Daily view of levels of interest. Need buyers to step in and break T5, I expect the day this happens we see immense volume step in and form T4 as a new based support moving forward. Alerts on watch. pic.twitter.com/FrOcPqeXzx
Ok let’s get $PRMO going soon 😎
— 🇵🇭PinayTigerTrades🗯 (@Brown_chickHB) September 1, 2022
$BYOC far from done. $PRMO chart indicating it could be next
— Bill's Stocks and Thoughts (@billsstocks1) August 31, 2022
Event based run with $CZNI vibes, possibly more. Volume precedes price on the chart. Also watching $PRMO (same custodian as the guy who ran $SPOM big back in 2020) for a trips run. Let's go $BYOC.
— Bill's Stocks and Thoughts (@billsstocks1) August 31, 2022
Prom Resources
PRMO : 0.0003
NO DEBT!!
https://www.otcmarkets.com/otcapi/company/financial-report/342698/content
PRMO is Pink Current again!
https://www.otcmarkets.com/stock/PRMO/overview
NEW WEBSITE: https://www.promrestaurants.com
Prom Resources, Inc.
https://www.barchart.com/stocks/quotes/PRMO/technical-chart?plot=CANDLE&volume=total&data=DO&density=M&pricesOn=1&asPctChange=0&logscale=0&indicators=ACCUM;HLMA(10,8);SMA(20);BBANDS(20,2);RSI(14,100);STOSL(14,3);SMACD(12,26,9);MOMENT(20);MFI(14,100);SMA(20)&sym=PRMO&grid=1&height=500&studyheight=100
Twitter:
https://twitter.com/johnvsuter/status/1585070526019817473$PRMO looks like the sellings stopped. One PR or volume spike takes it a few ticks imo
— FisherTrades (@Fisher_Trades) October 27, 2022
Good morning. Nice to see $PRMO is catching eyes again.
— Broker Amanda (@DFWagent) October 24, 2022
$PRMO many are sleeping on
— Bill's Stocks and Thoughts (@billsstocks1) September 23, 2022
— Bill's Stocks and Thoughts (@billsstocks1) September 20, 2022
Vamos $PRMO https://t.co/5FiYwrYKfi
— FOX (@Jorgeemartineze) September 20, 2022
$SNMN strong support @ 0.0006$NWPN strong support @ 0.0005 with multiple news catalyst $PRMO 0.0003 holding nicely
— Savage (@KEdelbrock) September 13, 2022
$PRMO Everyone is Buying the Dip Right Now.Hoarding Shares,... https://t.co/mNJLOKlEGH
— Anita Mccormick (@AnitaMc26910087) September 13, 2022
Starting to load $PAOG. $PRMO has great chart potential on an 0004 break. Plus PRMO has the custodian that ran SPOM big back in the day
— Bill's Stocks and Thoughts (@billsstocks1) September 9, 2022
$prmo
— mike ferr (@ferrante821) September 10, 2022
The loading is off the hook
Sooner or later it will run
$VNUE After Christmas went from 0037 to 012 on almost nothing. A couple weeks later, it went to over 04 under worse fundamentals.$PRMO still haven't been filled by the whackers but I'm happy with 14MM
— Bill's Stocks and Thoughts (@billsstocks1) September 6, 2022
$PRMO
— DB Daytrades (@DB_Daytrades) September 6, 2022
Daily view of levels of interest. Need buyers to step in and break T5, I expect the day this happens we see immense volume step in and form T4 as a new based support moving forward. Alerts on watch. pic.twitter.com/FrOcPqeXzx
Ok let’s get $PRMO going soon 😎
— 🇵🇭PinayTigerTrades🗯 (@Brown_chickHB) September 1, 2022
$BYOC far from done. $PRMO chart indicating it could be next
— Bill's Stocks and Thoughts (@billsstocks1) August 31, 2022
Event based run with $CZNI vibes, possibly more. Volume precedes price on the chart. Also watching $PRMO (same custodian as the guy who ran $SPOM big back in 2020) for a trips run. Let's go $BYOC.
— Bill's Stocks and Thoughts (@billsstocks1) August 31, 2022
Prom Resources
PRMO : 0.0003 + 50%
NO DEBT!!
https://www.otcmarkets.com/otcapi/company/financial-report/342698/content
PRMO is Pink Current again!
https://www.otcmarkets.com/stock/PRMO/overview
NEW WEBSITE: https://www.promrestaurants.com
Prom Resources, Inc.
https://www.barchart.com/stocks/quotes/PRMO/technical-chart?plot=CANDLE&volume=total&data=DO&density=M&pricesOn=1&asPctChange=0&logscale=0&indicators=ACCUM;HLMA(10,8);SMA(20);BBANDS(20,2);RSI(14,100);STOSL(14,3);SMACD(12,26,9);MOMENT(20);MFI(14,100);SMA(20)&sym=PRMO&grid=1&height=500&studyheight=100
Twitter:
https://twitter.com/johnvsuter/status/1585070526019817473$PRMO looks like the sellings stopped. One PR or volume spike takes it a few ticks imo
— FisherTrades (@Fisher_Trades) October 27, 2022
Good morning. Nice to see $PRMO is catching eyes again.
— Broker Amanda (@DFWagent) October 24, 2022
$PRMO many are sleeping on
— Bill's Stocks and Thoughts (@billsstocks1) September 23, 2022
— Bill's Stocks and Thoughts (@billsstocks1) September 20, 2022
Vamos $PRMO https://t.co/5FiYwrYKfi
— FOX (@Jorgeemartineze) September 20, 2022
$SNMN strong support @ 0.0006$NWPN strong support @ 0.0005 with multiple news catalyst $PRMO 0.0003 holding nicely
— Savage (@KEdelbrock) September 13, 2022
$PRMO Everyone is Buying the Dip Right Now.Hoarding Shares,... https://t.co/mNJLOKlEGH
— Anita Mccormick (@AnitaMc26910087) September 13, 2022
Starting to load $PAOG. $PRMO has great chart potential on an 0004 break. Plus PRMO has the custodian that ran SPOM big back in the day
— Bill's Stocks and Thoughts (@billsstocks1) September 9, 2022
$prmo
— mike ferr (@ferrante821) September 10, 2022
The loading is off the hook
Sooner or later it will run
$VNUE After Christmas went from 0037 to 012 on almost nothing. A couple weeks later, it went to over 04 under worse fundamentals.$PRMO still haven't been filled by the whackers but I'm happy with 14MM
— Bill's Stocks and Thoughts (@billsstocks1) September 6, 2022
$PRMO
— DB Daytrades (@DB_Daytrades) September 6, 2022
Daily view of levels of interest. Need buyers to step in and break T5, I expect the day this happens we see immense volume step in and form T4 as a new based support moving forward. Alerts on watch. pic.twitter.com/FrOcPqeXzx
Ok let’s get $PRMO going soon 😎
— 🇵🇭PinayTigerTrades🗯 (@Brown_chickHB) September 1, 2022
$BYOC far from done. $PRMO chart indicating it could be next
— Bill's Stocks and Thoughts (@billsstocks1) August 31, 2022
Event based run with $CZNI vibes, possibly more. Volume precedes price on the chart. Also watching $PRMO (same custodian as the guy who ran $SPOM big back in 2020) for a trips run. Let's go $BYOC.
— Bill's Stocks and Thoughts (@billsstocks1) August 31, 2022
Prom Resources
PRMO : 0.0003 + 50%
NO DEBT!!
https://www.otcmarkets.com/otcapi/company/financial-report/342698/content
PRMO is Pink Current again!
https://www.otcmarkets.com/stock/PRMO/overview
NEW WEBSITE: https://www.promrestaurants.com
Prom Resources, Inc.
https://www.barchart.com/stocks/quotes/PRMO/technical-chart?plot=CANDLE&volume=total&data=DO&density=M&pricesOn=1&asPctChange=0&logscale=0&indicators=ACCUM;HLMA(10,8);SMA(20);BBANDS(20,2);RSI(14,100);STOSL(14,3);SMACD(12,26,9);MOMENT(20);MFI(14,100);SMA(20)&sym=PRMO&grid=1&height=500&studyheight=100
Twitter:
https://twitter.com/johnvsuter/status/1585070526019817473$PRMO looks like the sellings stopped. One PR or volume spike takes it a few ticks imo
— FisherTrades (@Fisher_Trades) October 27, 2022
Good morning. Nice to see $PRMO is catching eyes again.
— Broker Amanda (@DFWagent) October 24, 2022
$PRMO many are sleeping on
— Bill's Stocks and Thoughts (@billsstocks1) September 23, 2022
— Bill's Stocks and Thoughts (@billsstocks1) September 20, 2022
Vamos $PRMO https://t.co/5FiYwrYKfi
— FOX (@Jorgeemartineze) September 20, 2022
$SNMN strong support @ 0.0006$NWPN strong support @ 0.0005 with multiple news catalyst $PRMO 0.0003 holding nicely
— Savage (@KEdelbrock) September 13, 2022
$PRMO Everyone is Buying the Dip Right Now.Hoarding Shares,... https://t.co/mNJLOKlEGH
— Anita Mccormick (@AnitaMc26910087) September 13, 2022
Starting to load $PAOG. $PRMO has great chart potential on an 0004 break. Plus PRMO has the custodian that ran SPOM big back in the day
— Bill's Stocks and Thoughts (@billsstocks1) September 9, 2022
$prmo
— mike ferr (@ferrante821) September 10, 2022
The loading is off the hook
Sooner or later it will run
$VNUE After Christmas went from 0037 to 012 on almost nothing. A couple weeks later, it went to over 04 under worse fundamentals.$PRMO still haven't been filled by the whackers but I'm happy with 14MM
— Bill's Stocks and Thoughts (@billsstocks1) September 6, 2022
$PRMO
— DB Daytrades (@DB_Daytrades) September 6, 2022
Daily view of levels of interest. Need buyers to step in and break T5, I expect the day this happens we see immense volume step in and form T4 as a new based support moving forward. Alerts on watch. pic.twitter.com/FrOcPqeXzx
Ok let’s get $PRMO going soon 😎
— 🇵🇭PinayTigerTrades🗯 (@Brown_chickHB) September 1, 2022
$BYOC far from done. $PRMO chart indicating it could be next
— Bill's Stocks and Thoughts (@billsstocks1) August 31, 2022
Event based run with $CZNI vibes, possibly more. Volume precedes price on the chart. Also watching $PRMO (same custodian as the guy who ran $SPOM big back in 2020) for a trips run. Let's go $BYOC.
— Bill's Stocks and Thoughts (@billsstocks1) August 31, 2022
CarSmartt, Inc.
https://smarttholdings.com/
CRSM: 0,0030
https://www.otcmarkets.com/stock/CRSM/disclosure
Big news is coming
https://twitter.com/car_smartt/status/1516402977753419776
https://twitter.com/car_smartt/status/1517542931376349184?cxt=HHwWgIC9wa_Qso8qAAAA
Our share structure has remained the same since last year.
As of 08/30/2021, the number of shares outstanding of our Common Stock was:
595,304,566
11/02/2022
Outstanding Shares
595,304,566
11/02/2022
Float
175,117,101
11/02/2022
= less than 0.6 million in the free float.
no dilution so room for a big rebound
Feb 23, 2022 0.0060
Jan 19, 2022 0.0084
Oct 25, 2021 0.0120
Sep 27, 2021 0.0169
Aug 23, 2021 0.0290
Jul 26, 2021 0.0550
Monday Watch$IGEX $SYSX $DVLP
— Tactical Trading (Penny Stocks) (@JohnRSpano1) May 2, 2022
MAY Watch$SYSX $IGEX $APTY $ETEK $DVLP $MONI $PRCX $CYBL $DUTV $CRSM $HIPH $NGCG $SNPW $LCLP $SDRC $BYRG $KATX
~Let's Get That 💰~
CarSmartt, Inc.
https://smarttholdings.com/
CRSM: 0,0030
https://www.otcmarkets.com/stock/CRSM/disclosure
Big news is coming
https://twitter.com/car_smartt/status/1516402977753419776
https://twitter.com/car_smartt/status/1517542931376349184?cxt=HHwWgIC9wa_Qso8qAAAA
Our share structure has remained the same since last year.
As of 08/30/2021, the number of shares outstanding of our Common Stock was:
595,304,566
11/02/2022
Outstanding Shares
595,304,566
11/02/2022
Float
175,117,101
11/02/2022
= less than 0.6 million in the free float.
no dilution so room for a big rebound
Feb 23, 2022 0.0060
Jan 19, 2022 0.0084
Oct 25, 2021 0.0120
Sep 27, 2021 0.0169
Aug 23, 2021 0.0290
Jul 26, 2021 0.0550
Monday Watch$IGEX $SYSX $DVLP
— Tactical Trading (Penny Stocks) (@JohnRSpano1) May 2, 2022
MAY Watch$SYSX $IGEX $APTY $ETEK $DVLP $MONI $PRCX $CYBL $DUTV $CRSM $HIPH $NGCG $SNPW $LCLP $SDRC $BYRG $KATX
~Let's Get That 💰~
Prom Resources
PRMO : 0.0003 + 50%
Volume: 51.862.249
NO DEBT!!
https://www.otcmarkets.com/otcapi/company/financial-report/342698/content
PRMO is Pink Current again!
https://www.otcmarkets.com/stock/PRMO/overview
NEW WEBSITE: https://www.promrestaurants.com
Prom Resources, Inc.
https://www.barchart.com/stocks/quotes/PRMO/technical-chart?plot=CANDLE&volume=total&data=DO&density=M&pricesOn=1&asPctChange=0&logscale=0&indicators=ACCUM;HLMA(10,8);SMA(20);BBANDS(20,2);RSI(14,100);STOSL(14,3);SMACD(12,26,9);MOMENT(20);MFI(14,100);SMA(20)&sym=PRMO&grid=1&height=500&studyheight=100
Twitter:
https://twitter.com/johnvsuter/status/1585070526019817473$PRMO looks like the sellings stopped. One PR or volume spike takes it a few ticks imo
— FisherTrades (@Fisher_Trades) October 27, 2022
Good morning. Nice to see $PRMO is catching eyes again.
— Broker Amanda (@DFWagent) October 24, 2022
$PRMO many are sleeping on
— Bill's Stocks and Thoughts (@billsstocks1) September 23, 2022
— Bill's Stocks and Thoughts (@billsstocks1) September 20, 2022
Vamos $PRMO https://t.co/5FiYwrYKfi
— FOX (@Jorgeemartineze) September 20, 2022
$SNMN strong support @ 0.0006$NWPN strong support @ 0.0005 with multiple news catalyst $PRMO 0.0003 holding nicely
— Savage (@KEdelbrock) September 13, 2022
$PRMO Everyone is Buying the Dip Right Now.Hoarding Shares,... https://t.co/mNJLOKlEGH
— Anita Mccormick (@AnitaMc26910087) September 13, 2022
Starting to load $PAOG. $PRMO has great chart potential on an 0004 break. Plus PRMO has the custodian that ran SPOM big back in the day
— Bill's Stocks and Thoughts (@billsstocks1) September 9, 2022
$prmo
— mike ferr (@ferrante821) September 10, 2022
The loading is off the hook
Sooner or later it will run
$VNUE After Christmas went from 0037 to 012 on almost nothing. A couple weeks later, it went to over 04 under worse fundamentals.$PRMO still haven't been filled by the whackers but I'm happy with 14MM
— Bill's Stocks and Thoughts (@billsstocks1) September 6, 2022
$PRMO
— DB Daytrades (@DB_Daytrades) September 6, 2022
Daily view of levels of interest. Need buyers to step in and break T5, I expect the day this happens we see immense volume step in and form T4 as a new based support moving forward. Alerts on watch. pic.twitter.com/FrOcPqeXzx
Ok let’s get $PRMO going soon 😎
— 🇵🇭PinayTigerTrades🗯 (@Brown_chickHB) September 1, 2022
$BYOC far from done. $PRMO chart indicating it could be next
— Bill's Stocks and Thoughts (@billsstocks1) August 31, 2022
Event based run with $CZNI vibes, possibly more. Volume precedes price on the chart. Also watching $PRMO (same custodian as the guy who ran $SPOM big back in 2020) for a trips run. Let's go $BYOC.
— Bill's Stocks and Thoughts (@billsstocks1) August 31, 2022
Prom Resources
PRMO : 0.0003 + 50%
Volume: 51.862.249
NO DEBT!!
https://www.otcmarkets.com/otcapi/company/financial-report/342698/content
PRMO is Pink Current again!
https://www.otcmarkets.com/stock/PRMO/overview
NEW WEBSITE: https://www.promrestaurants.com
Prom Resources, Inc.
https://www.barchart.com/stocks/quotes/PRMO/technical-chart?plot=CANDLE&volume=total&data=DO&density=M&pricesOn=1&asPctChange=0&logscale=0&indicators=ACCUM;HLMA(10,8);SMA(20);BBANDS(20,2);RSI(14,100);STOSL(14,3);SMACD(12,26,9);MOMENT(20);MFI(14,100);SMA(20)&sym=PRMO&grid=1&height=500&studyheight=100
Twitter:
https://twitter.com/johnvsuter/status/1585070526019817473$PRMO looks like the sellings stopped. One PR or volume spike takes it a few ticks imo
— FisherTrades (@Fisher_Trades) October 27, 2022
Good morning. Nice to see $PRMO is catching eyes again.
— Broker Amanda (@DFWagent) October 24, 2022
$PRMO many are sleeping on
— Bill's Stocks and Thoughts (@billsstocks1) September 23, 2022
— Bill's Stocks and Thoughts (@billsstocks1) September 20, 2022
Vamos $PRMO https://t.co/5FiYwrYKfi
— FOX (@Jorgeemartineze) September 20, 2022
$SNMN strong support @ 0.0006$NWPN strong support @ 0.0005 with multiple news catalyst $PRMO 0.0003 holding nicely
— Savage (@KEdelbrock) September 13, 2022
$PRMO Everyone is Buying the Dip Right Now.Hoarding Shares,... https://t.co/mNJLOKlEGH
— Anita Mccormick (@AnitaMc26910087) September 13, 2022
Starting to load $PAOG. $PRMO has great chart potential on an 0004 break. Plus PRMO has the custodian that ran SPOM big back in the day
— Bill's Stocks and Thoughts (@billsstocks1) September 9, 2022
$prmo
— mike ferr (@ferrante821) September 10, 2022
The loading is off the hook
Sooner or later it will run
$VNUE After Christmas went from 0037 to 012 on almost nothing. A couple weeks later, it went to over 04 under worse fundamentals.$PRMO still haven't been filled by the whackers but I'm happy with 14MM
— Bill's Stocks and Thoughts (@billsstocks1) September 6, 2022
$PRMO
— DB Daytrades (@DB_Daytrades) September 6, 2022
Daily view of levels of interest. Need buyers to step in and break T5, I expect the day this happens we see immense volume step in and form T4 as a new based support moving forward. Alerts on watch. pic.twitter.com/FrOcPqeXzx
Ok let’s get $PRMO going soon 😎
— 🇵🇭PinayTigerTrades🗯 (@Brown_chickHB) September 1, 2022
$BYOC far from done. $PRMO chart indicating it could be next
— Bill's Stocks and Thoughts (@billsstocks1) August 31, 2022
Event based run with $CZNI vibes, possibly more. Volume precedes price on the chart. Also watching $PRMO (same custodian as the guy who ran $SPOM big back in 2020) for a trips run. Let's go $BYOC.
— Bill's Stocks and Thoughts (@billsstocks1) August 31, 2022
EAGLE PHARMACEUTICALS INC (EGRX) 34,75 + 10.16%
52w High: 56.43
TIME FOR A STRONG RECOVERY:
Total revenue for Q3 2022 was $65.9 million, compared to $39.9 million in Q3 2021
Nine-month 2022 net income was $2.41 per basic and $2.38 per diluted share
Nine-month 2022 adjusted non-GAAP earnings per diluted share1 more than doubled to $6.69 from full year 2021 adjusted non-GAAP earnings per diluted share, outperforming any full year in the Company’s history
Nine-month 2022 revenue of $255.9 million exceeds full year 2021 revenue of $171.5 million
Nine-month 2022 net sales of vasopressin and PEMFEXY combined totaled $114.9 million
BENDEKA®2 and BELRAPZO®3 - both ready-to-dilute (“RTD”) products — combined currently have 91% share of the bendamustine market, up from 85% at the beginning of the year. TREANDA®4, which is not an RTD product, has just 9%5
Q3 2022 gross profit from bendamustine franchise increased 9% compared to Q3 20216
Submitted an investigational new drug (“IND”) application to the U.S. Food and Drug Administration (“FDA”) for CAL02, a novel first-in-class broad-spectrum anti-virulence agent for the treatment of severe community-acquired bacterial pneumonia
Strengthened hospital pipeline through equity stake in and an option to acquire Enalare Therapeutics Inc (“Enalare”)7. Enalare’s lead pipeline compound, ENA-001, a novel agnostic respiratory stimulant with strong patent protection, has three target indications: post-operative respiratory depression; community drug overdose; and Apnea of Prematurity, a common condition in preterm infants
Company to host Investor Day in New York City on December 6, 2022
WOODCLIFF LAKE, N.J., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced financial results for the three and nine months ended September 30, 2022.
Business and Recent Highlights:
Submitted an IND application to FDA for CAL02, a novel first-in-class broad-spectrum anti-virulence agent for the treatment of severe community-acquired bacterial pneumonia (“SCABP”). The IND filing includes a protocol for an adequately powered global Phase 2 study to evaluate the efficacy and safety of CAL02 when added to standard of care therapy in patients with SCABP.
Acquired an equity stake in, with an option to purchase, Enalare Therapeutics Inc. (“Enalare”), adding a portfolio of novel NCEs with strong intellectual property protection, from the mid-2030s into the 2040s, including composition of matter patents. Enalare’s lead compound, ENA-001 is an investigational, one-of-a-kind NCE being developed as an agnostic respiratory stimulant for multiple patient populations experiencing acute respiratory depression. The initial targeted indications include post-operative respiratory depression; community drug overdose; and Apnea of Prematurity, a common condition in preterm infants. The Company believes this investment strengthens Eagle’s position as a diversified pharmaceutical company and a leader in hospital/anesthesia.
Enalare secured a contract for up to $50.3 million from the Biomedical Advanced Research and Development Authority (“BARDA”), part of the Administration for Strategic Preparedness and Response in the U.S. Department of Health and Human Services (contract number 75A50122C00072). In partnership with BARDA, ENA-001 is being developed in an intramuscular (“IM”) formulation for potential use in patients experiencing community drug overdose and as a potential medical countermeasure for mass casualty events.
FDA granted Orphan Drug Designation (“ODD”) to ENA-001 for the treatment of Apnea of Prematurity (“AoP”). AoP is a development disorder attributed to immaturity of the pulmonary system characterized by either cessation of breathing for more than 20 seconds or cessation of breathing that lasts less than 20 seconds but is accompanied by either bradycardia or hypoxemia.
Received favorable ruling in vasopressin litigation. The U.S. Court of Appeals for the Federal Circuit affirmed the U.S. District Court for the District of Delaware’s decision that Eagle’s vasopressin product does not infringe on any of the patents asserted by Par Pharmaceutical, Inc.
Appointed pharmaceutical industry veteran, Debra M. Hussain, as Senior Vice President, Head of Commercial, with responsibility for FDA-approved new chemical entities, BARHEMSYS® and BYFAVO®, acquired as part of the acquisition of Acacia Pharma Group plc (“Acacia”).
Amended and restated its credit agreement providing for a three-year $100 million revolving credit facility and $50 million term loan facility and repaid all other debt.
Financial Highlights
Third Quarter 2022
Total revenue for Q3 2022 was $65.9 million, compared to $39.9 million in Q3 2021.
Q3 2022 net loss was $(3.5) million, or $(0.27) per basic and diluted share, compared to net loss of $(5.6) million, or $(0.43) per basic and diluted share, in Q3 2021.
Q3 2022 adjusted non-GAAP net income was $14.9 million, or $1.13 per basic and $1.12 per diluted share, compared to adjusted non-GAAP net income of $7.5 million, or $0.57 per basic and $0.56 per diluted share, in Q3 2021.
Cash and cash equivalents were $15.4 million, net accounts receivable was $96.9 million, and debt was $59.3 million, as of September 30, 2022.
Recorded a $3.8 million milestone payment from SymBio on TREAKISYM® in Q3 2022, $1.2 million ($0.07 per basic and diluted share) less than anticipated due to currency declines of the Japanese Yen.
“It was another strong quarter for Eagle, and we are pleased that the earnings growth has continued. We are posting record earnings this year, as evidenced by the fact that in the first nine months of the year, we have already earned $6.69 per share, topping our previous best full year ever,” stated Scott Tarriff, President and Chief Executive Officer of Eagle Pharmaceuticals.
“We expect another strong year in 2023 and anticipate deploying the cash from our earnings and strong balance sheet not only to fund our key clinical initiatives but also to potentially make an accretive acquisition to round out our portfolio. Between business development activities and our own R&D engine, we believe Eagle can grow significantly larger as it transitions into a branded pharmaceutical company with a diversified portfolio of assets,” concluded Tarriff.
Third Quarter 2022 Financial Results
Total revenue for the three months ended September 30, 2022 was $65.9 million, as compared to $39.9 million for the three months ended September 30, 2021.
Q3 2022 RYANODEX® net product sales were $7.6 million, compared to $4.5 million in the third quarter of 2021.
Q3 2022 BELRAPZO net product sales were $8.5 million, compared to $4.9 million in the third quarter of 2021.
Q3 2022 PEMFEXY® net product sales were $1.7 million and vasopressin net product sales were $13.8 million.